Fox Chase Cancer Center News

PHILADELPHIA (December 10, 2017) – According to a new study, autologous hematopoietic cell transplant (HCT) administered in first remission led to longer overall survival in younger patients with mantle cell lymphoma. Researchers found that patients who received HCT once initial chemotherapy had caused remission experienced a 40 percent improvement in progression free survival and more than 20 increase in overall survival compared with eligible patients who did not receive it.

PHILADELPHIA (December 7, 2017) – A small, but significant proportion of patients with invasive breast cancer have at least one of three biomarkers linked to immune check point blockade (ICB) therapy, suggesting a role for such treatment for certain breast cancers, a new study shows. 

PHILADELPHIA (December 7, 2017) – Researchers at Fox Chase Cancer Center have found a new link between estrogen and lung cancer among never-smokers and smokers: that human lungs can metabolize the hormone estrogen, yielding a carcinogenic derivative.

PHILADELPHIA (December 5, 2017) — Lori J. Goldstein, MD, FASCO, Deputy Associate Director of Clinical Research,  Professor of Medical Oncology and the Director of Naomi and Phil Lippincott Breast Evaluation Center at Fox Chase Cancer Center, is one of 27 breast oncologists across the country being recognized by Forbes as an exemplary physician in the field of oncology.

PHILADELPHIA (December 1, 2017) – Fox Chase Cancer Center is raising awareness on the risk factors for lung cancer. Lung cancer is the second most common cancer in both men and women, and the leading cause of cancer death, according to the American Cancer Society (ACS), and is by far the leading cause of cancer death.

PHILADELPHIA (December 1, 2017) – HIV patients who are treated with combination anti-retroviral therapy (cART) can safely undergo chemotherapy to treat associated lymphomas at the same time, researchers from the AIDS Malignancy Consortium, including Fox Chase Cancer Center have found.

Saturday December 2nd and Thursday December 7th, 2017.

PHILADELPHIA (November 24, 2017) – Researchers at Fox Chase Cancer Center and the Johns Hopkins University School of Medicine have identified two new subtypes of laryngeal cancer, each of which indicates different survival outcomes for patients. These findings, which for the first time linked better survival to mutations damaging the genes NSD1 and NSD2, were validated in an independent cohort of patients treated at Fox Chase and Johns Hopkins.